Impact of Newly Diagnosed Left Bundle Branch Block on Long-Term Outcomes in Patients with STEMI

Larisa Anghel1,2, Cristian Stătescu1,2, Radu Andy Sascău1,2

  • 1Internal Medicine Department, "Grigore T. Popa" University of Medicine and Pharmacy, 700503 Iași, Romania.

Journal of Clinical Medicine
|September 28, 2024
PubMed

Insights

Newly developed left bundle branch block (LBBB) in ST-elevation myocardial infarction (STEMI) patients significantly increases long-term risks for adverse outcomes, including mortality. Early intervention for factors like reduced ejection fraction is crucial for improving prognosis.

Area of Science:

  • Cardiology
  • Clinical Research
  • Internal Medicine

Background:

  • Left bundle branch block (LBBB) is a known cardiac condition.
  • Its prognostic implications in ST-elevation myocardial infarction (STEMI) patients with single coronary lesions are not fully understood.
  • Primary percutaneous coronary intervention (PCI) is a standard treatment for STEMI.

Purpose of the Study:

  • To assess the long-term prognostic significance of new-onset LBBB in STEMI patients with a single coronary lesion after primary PCI.
  • To identify predictors of adverse outcomes in this patient cohort.

Main Methods:

  • Retrospective analysis of 3526 STEMI patients admitted between 2011-2013.
  • Identified 42 patients with new-onset LBBB and a single coronary lesion, compared to 42 STEMI patients without LBBB.
  • Prospective follow-up for a median of 9.4 years, analyzing demographic, clinical, and laboratory data.

Main Results:

  • Patients with new-onset LBBB (n=42) showed significantly higher rates of recurrent myocardial infarction, revascularization, and mortality compared to controls (n=42).
  • Multivariate analysis identified LBBB (HR: 2.15), lower left ventricular ejection fraction (LVEF) (HR: 1.45), and longer pain-to-admission time (HR: 1.32) as independent predictors of adverse outcomes.
  • Baseline characteristics were similar between the groups.

Conclusions:

  • Newly acquired LBBB in STEMI patients is associated with poorer long-term prognosis.
  • Early identification and management of reduced LVEF and timely hospital admission are vital for improving outcomes in STEMI patients with new-onset LBBB.

Related Concept Videos

Acute Coronary Syndrome II: Pathophysiology and clinical manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and clinical manifestations

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
3
Acute Coronary SyndromeI: Introduction01:30

Acute Coronary SyndromeI: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
15
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
2
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
320
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
6
Acute Coronary Syndrome III: Diagnostic studies01:30

Acute Coronary Syndrome III: Diagnostic studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
3